Curis (NASDAQ:CRIS) Cut to “Sell” at Zacks Investment Research

Zacks Investment Research cut shares of Curis (NASDAQ:CRIS) from a buy rating to a sell rating in a research note issued to investors on Tuesday, reports.

According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “

Separately, Raymond James assumed coverage on Curis in a research report on Wednesday, October 13th. They set an outperform rating and a $15.00 price objective for the company. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. According to data from, the stock presently has a consensus rating of Buy and an average price target of $17.38.

CRIS opened at $3.65 on Tuesday. The firm has a market cap of $334.37 million, a P/E ratio of -7.93 and a beta of 2.78. Curis has a 52-week low of $3.17 and a 52-week high of $17.40. The business’s fifty day moving average is $4.84 and its 200-day moving average is $6.68.

Curis (NASDAQ:CRIS) last released its quarterly earnings data on Monday, November 8th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.01. The business had revenue of $3.04 million for the quarter, compared to analyst estimates of $2.66 million. Curis had a negative return on equity of 33.62% and a negative net margin of 373.25%. During the same period last year, the firm posted ($0.11) earnings per share. As a group, equities analysts anticipate that Curis will post -0.48 EPS for the current year.

Several large investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada grew its position in Curis by 21.1% during the third quarter. Royal Bank of Canada now owns 10,124 shares of the biotechnology company’s stock worth $80,000 after buying an additional 1,767 shares in the last quarter. Advisor Group Holdings Inc. boosted its holdings in shares of Curis by 36.1% in the 3rd quarter. Advisor Group Holdings Inc. now owns 7,540 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 2,000 shares in the last quarter. Moors & Cabot Inc. purchased a new stake in Curis during the 3rd quarter valued at about $268,000. LPL Financial LLC boosted its holdings in Curis by 8.6% during the 3rd quarter. LPL Financial LLC now owns 37,752 shares of the biotechnology company’s stock valued at $296,000 after acquiring an additional 3,000 shares during the period. Finally, Total Clarity Wealth Management Inc. purchased a new stake in Curis during the 3rd quarter valued at about $50,000. Institutional investors own 80.61% of the company’s stock.

About Curis

Curis, Inc engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints.

See Also: FTSE 100 Index

Get a free copy of the Zacks research report on Curis (CRIS)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with's FREE daily email newsletter.